PDF下载 ( 835 KB)
IRE1α/TRAF2/JNK信号通路在急性肝衰竭发展中的作用机制及潜在价值
DOI: 10.12449/JCH240633
利益冲突声明：本文不存在任何利益冲突。
作者贡献声明：关海梅负责拟定写作思路并撰写文章；陈玮钰、曾阳玲负责设计论文框架；李国宝、张日云负责收集、整理相关文献；王恬雯、谢宝华负责修订论文；毛德文、张衎提供指导意见并最后定稿。
Mechanism of action and potential value of the IRE1α/TRAF2/JNK pathway in the progression of acute liver failure
-
摘要: 急性肝衰竭（ALF）是临床上最危重的一种肝脏疾病，严重影响我国人民生命健康。由于ALF的发病率和死亡率高、发病机制不明确、治疗手段有限，成为肝病领域亟待解决的重大难题。近年来，越来越多研究表明，内质网应激是ALF进展中一个关键的生物学过程，IRE1α/TRAF2/JNK通路作为内质网应激信号传导的一部分，在疾病的发展中发挥着放大炎症反应、促进肝细胞凋亡、抑制肝再生能力等作用。而中医药作为我国传统瑰宝，从中药单体中寻找有效防治ALF的药物成为研究热点。本文旨在通过阐述IRE1α/TRAF2/JNK通路在ALF发展中的作用机制，以及总结红景天苷、楮实子、补骨脂+五味子、黄芩素、京尼平、山柰酚、白藜芦醇、沙棘多糖提取物、木犀草素等中药单体调控该通路的潜在价值，以期为ALF的进一步研究和临床实践提供参考依据。Abstract: Acute liver failure （ALF） is one of the most critical liver diseases in clinical practice and seriously affects the life and health of Chinese people. Due to its high morbidity and mortality rates， unclear pathogenesis， and limited treatment methods， ALF has become a major problem that needs to be solved urgently in the field of liver diseases. In recent years， more and more studies have shown that endoplasmic reticulum stress is a key biological process in the progression of ALF， and the IRE1α/TRAF2/JNK pathway， as a part of endoplasmic reticulum stress signaling， plays a role in amplifying inflammatory response， promoting hepatocyte apoptosis， and inhibiting liver regeneration ability during the progression of diseases. As a traditional treasure of China， traditional Chinese medicine has become a research hotspot in search for effective prevention and treatment drugs for ALF from monomers of Chinese herbs. This article elaborates on the mechanism of action of the IRE1α/TRAF2/JNK pathway in the progression of ALF and summarizes the potential value of several monomers of Chinese herbs in regulating this pathway， such as salidroside， Fructus Broussonetiae， Fructus Psoraleae+Schisandra chinensis， baicalein， genipin， kaempferol， resveratrol， sea buckthorn polysaccharide extract， and luteol， in order to provide a reference for further research and clinical practice of ALF.
-
Key words:
- Liver Failure， Acute /
- Signal Transduction /
- Endoplasmic Reticulum Stress
-
慢加急性肝衰竭（acute-on-chronic liver failure，ACLF）是在慢性肝病（包括慢性肝炎或肝硬化）基础上因各种诱因引起的急性肝衰竭，病情进展快，病死率达60%～80%。肝移植是挽救ACLF患者的最终手段，然而由于治疗费用高、供体肝脏少、技术难度较大等问题使其极大程度地受到了限制。近年来，人工肝治疗技术发展迅速，临床疗效肯定。大量研究［1-3］证明人工肝是治疗ACLF的有效措施。但血液通过管路和血浆分离器时血细胞的成分有一定的破坏，当血小板过低时，有增加出血的危险，在一定程度上限制了人工肝的治疗。由乙烯和乙烯醇共聚物制备的Evacure-4A膜型血浆分离器由于截孔面积小，膜交换面积大，组织相容性好，可以耐受高达250 mmHg的跨膜压，且随物质分子量的加大而筛选系数越来越低，因此血液通过时对血细胞的影响较小。叶俊茂等［4］研究表明，使用Evacure-4A膜型血浆分离器进行血浆置换治疗慢性重型肝炎伴严重血小板减少患者是安全的。本研究通过对不同分层血小板计数ACLF患者据病情选择不同模式非生物型人工肝治疗，观察其疗效及安全性。
1. 资料与方法
1.1 研究对象
选取2021年1月—2023年5月入住本院的ACLF患者，根据血小板计数将其分为3组：A组（明显低下组），25×109/L～50×109/L；B组（中等程度低下组），51×109/L～80×109/L；C组（轻度低下组），81×109/L～100×109/L。纳入标准：ACLF诊断符合《肝衰竭诊治指南（2018年版）》［5］。排除标准：（1）合并肿瘤、妊娠、原发性心源性休克、原发性肾衰竭且规律透析、肝移植患者；（2）血小板计数<25×109/L的患者；（3）活动性出血的患者；（4）合并血液系统恶性病的患者，如血液肿瘤、骨髓抑制；使用具有明确骨髓抑制药物的患者；（5）入院前至住院1周有明确出血的患者；（6）近期有使用抗血小板药物的患者；（7）既往接受过脾脏切除术的患者；（8）不愿参加本研究者。
1.2 方法
1.2.1 内科综合治疗
包括卧床休息，静脉滴注多烯磷脂酰胆碱、丁二磺酸腺苷蛋氨酸、复方甘草酸苷等保肝及人血白蛋白等支持治疗，乙型肝炎有抗病毒治疗指征者加用恩替卡韦或富马酸替诺福韦二吡呋酯或富马酸丙酚替诺福韦，同时依据病情联合不同模式人工肝治疗。
1.2.2 人工肝支持治疗
在持续空气消毒的人工肝治疗室内，心电监护下行股静脉穿刺置入股静脉双腔管建立体外循环，治疗过程中使用低分子肝素抗凝，根据患者凝血时间、体质量、跨膜压、分浆流速及治疗时间调整其剂量，使用Evacure-4A膜型选择性血浆分离器（旭化成医疗株式会社，日本）。治疗方式包括：血浆灌流联合血浆置换（plasma perfusion combined with plasma exchange，PP+PE）、胆红素吸附联合血浆置换（plasma bilirubin adsorption combined with plasma exchange，PBA+PE）、双重血浆分子吸附联合血浆置换（double plasma molecular adsorption combined with plasma exchange，DPMAS+PE）：使用德国贝朗Dia Pact CRRT机，采用BS330血浆胆红素吸附器（珠海健帆生物科技股份有限公司）和大分子树脂HA-330 Ⅱ型灌流器（广东丽珠医用生物），治疗过程血流量100～130 mL/min，时间2～3 h［6］，每次置换血浆量1 500 mL［7］，在置换血浆前常规应用10%葡萄糖酸钙3 g及地塞米松5 mg静注，预防过敏等不良反应。
1.3 观察指标
人工肝治疗前后患者临床症状、体征、肝功能、国际标准化比值（INR）、血小板计数，相关检验数据系人工肝后立即采集。采用Labospect 008全自动生化分析仪和迈克生物生化试剂检测肝功能各项指标，包括ALT、AST、Alb、TBil；INR由Sysmex CS-2000血凝仪及武汉中太生物技术有限公司血凝试剂进行检测；血小板计数由Sysmex XF-2000检测。记录治疗过程中的不良反应。
1.4 统计学方法
采用SPSS 19.0软件对数据进行统计分析。符合正态分布的计量资料以
2. 结果
2.1 一般资料
共纳入行人工肝治疗的ACLF患者302例，其中男236例（78.15%），女66例（21.85%），年龄24～87岁，中位年龄51.3岁。A组101例，男82例、女19例，平均年龄（51.75±11.38）岁；B组98例，男75例、女23例，平均年龄（51.53±10.96）岁；C组103例，男81例、女22例，平均年龄（50.72±12.49）岁。3组患者一般资料比较，年龄、性别、治疗前各组INR、Alb差异均无统计学意义（P值均>0.05）（表1）。
表 1 血小板计数不同分层ACLF患者的一般资料比较Table 1. Comparison of general data of ACLF patients with different levels of platelet count组别 例数 男/女（例） 年龄（岁） INR Alb（g/L） A组 101 82/19 51.75±11.38 2.11±0.71 27.79±3.76 B组 98 75/23 51.53±10.96 1.98±0.46 28.79±3.61 C组 103 81/22 50.72±12.49 2.11±0.77 28.97±3.59 统计值 F=0.223 F=1.221 F=3.058 P值 0.723 0.804 0.361 0.060 2.2 3组患者治疗前后临床症状、肝功能、INR及血小板变化
302例ACLF患者治疗后有268例临床症状呈不同程度的改善，表现为精神好转，乏力减轻，食欲增加，腹胀缓解，未见明显出血倾向。各组治疗前后比较ALT、AST、TBil呈不同程度下降，肝功能好转（P值均<0.001）。INR呈不同程度降低，各组治疗前后比较，差异亦有统计学意义（P值均<0.05）。血小板计数呈不同程度的下降，但A组治疗前后无统计学差异（P>0.05）（表2）。
表 2 血小板计数不同分层ACLF患者人工肝治疗前后肝功能、凝血、血小板变化Table 2. Changes of liver function， blood coagulation and platelet count in patients with ACLF before and after artificial liver treatment分组 例数 ALT（U/L） AST（U/L） Alb（g/L） TBil（μmol/L） INR 血小板计数（×109/L） A组 101 治疗前 1.97±0.34 2.05±0.33 27.79±3.76 322.30±149.56 2.11±0.71 37.73±6.27 治疗后 1.78±0.28 1.88±0.31 25.71±2.79 197.25±103.20 1.91±0.66 36.59±7.96 t值 14.755 11.491 9.650 19.182 3.497 1.820 P值 <0.001 <0.001 <0.001 <0.001 0.001 0.072 B组 98 治疗前 2.06±0.43 2.09±0.37 28.79±3.61 262.28±113.56 1.98±0.46 66.97±7.64 治疗后 1.87±0.38 1.90±0.32 25.78±3.89 159.23±78.79 1.86±0.56 62.59±7.37 t值 21.614 19.301 7.878 17.486 3.327 12.993 P值 <0.001 <0.001 <0.001 <0.001 0.001 <0.001 C组 103 治疗前 2.37±0.50 2.31±0.44 28.97±3.59 311.16±128.73 2.11±0.77 93.82±5.38 治疗后 2.11±0.44 2.07±0.36 26.26±3.27 183.96±96.01 1.89±0.80 85.99±12.49 t值 15.965 13.919 8.045 21.750 4.358 8.240 P值 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 2.3 3组患者人工肝治疗不同模式构成情况
A、B、C组行PP+PE患者分别为40例（40%）、44例（45%）、41例（40%）；行DPMAS+PE患者分别为32例（32%）、30例（31%）、35例（34%）；行PBA+PE患者分别为29例（28%）、24例（24%）、27例（26%）。3组ACLF患者人工肝治疗模式各组间比较差异无统计学意义（
2.4 3组患者人工肝治疗过程中不良反应比较
ACLF患者人工肝治疗中最常见的不良反应为血浆过敏，发生率15.23%（46/302），较少见的不良反应为凝血，发生率0.66%（2/302），其余不良反应为低血压4.64%（14/302）、畏寒寒战0.99%（3/302）。3组患者发生不良反应分别有19例、21例、25例，发生率比较差异无统计学意义（18.81% vs 21.43% vs 24.27%，
3. 讨论
肝脏具有合成、代谢、解毒和生物转化功能，在维持人体正常凝血功能中具有重要作用。肝脏受损时，会导致凝血因子合成减少或其活性降低，进而伴随凝血机制和纤溶功能异常，表现为多种凝血功能障碍，INR也会相应的延长。当前，ACLF是一种无法完全治愈的综合征。具有发病率高、发病机制复杂、治疗难度大、预后极差等特点［8］。治疗的关键是早期诊断、积极预防、控制疾病诱因。治疗的主要原则是提供衰竭器官的功能支持、促进肝功能恢复。人工肝是目前其他方案无法替代的治疗手段［9-10］，已被纳入肝衰竭治疗的指南中。血清TBil是反映肝功能损害严重程度的可靠指标，INR是肝衰竭早期预警和病情进展的敏感指标，与患者预后显著相关［11-13］。杨景毅等［14］研究表明INR和TBil是影响ACLF患者预后的独立危险因素。本研究结果显示：3组患者治疗前TBil分别由（322.30±149.56）μmol/L、（262.28±113.56）μmol/L、（311.16±128.73）μmol/L下降至治疗后（197.25±103.20）μmol/L、（159.23±78.79）μmol/L、（183.96±96.01）μmol/L，ALT、AST亦呈不同程度下降，肝功能好转，INR分别由治疗前2.11±0.71、1.98±0.46、2.11±0.77降至治疗后1.91±0.66、1.86±0.56、1.89±0.80，且均有统计学差异（P值均<0.05）。说明人工肝治疗能改善ACLF患者的肝功能及INR。3组治疗后约88.74%患者乏力、腹胀等临床症状呈不同程度的改善。在前期的临床研究［7，15-16］中，使用不同模式人工肝治疗重型肝炎亦取得了较好的临床效果，包括肝功能好转、凝血功能改善、临床症状减轻。
ACLF的发病机制尚不明确，近年来大量研究证据表明全身炎症反应是驱动肝病进展的重要因素。Moreau等［17］研究显示，ACLF患者体内白细胞和急性反应时相蛋白水平更高；Clària等［18］研究表明，ACLF患者比非ACLF患者有着更高的炎症相关细胞因子和全身氧化应激标志物。人工肝支持系统的主要作用是为患者提供暂时的代谢支持，清除血液中过多的胆红素、内毒素、致炎因子等，维持内环境的稳定，为肝细胞再生创造条件。其原理是将患者的血液引出，通过膜型血浆分离器将血液的有形成分（血细胞）和血浆分离，分离出的血浆按20％～30％的比例丢弃，再补充等量正常人的新鲜血浆并和患者的血细胞混合后由静脉输入，形成循环回路。由于血浆分离的效果受膜的性质、血浆成分、血流量、跨膜压及滤过分数的影响，故选用制膜材料和制膜工艺不同的膜型血浆分离器，所带来的临床效果也不尽相同。如使用聚乙烯磺基制备的Plasman 06膜型血浆分离器进行血浆置换治疗，治疗后血小板平均下降22.17×109/L［4］。因此，当血小板过低时，血浆置换后有增加出血的危险。人工肝治疗一般要求患者血小板计数在50×109/L以上，而有些肝衰竭患者因有长期肝病史，或伴脾功能亢进，或在肝硬化基础上发生，常伴有明显的血小板减少，血小板计数常在50×109/L以下，当病情需要人工肝治疗时则会受到一定的限制。罗玲等［19］研究表明人工肝血浆置换治疗中Evacure-4A膜型血浆分离器对血小板无明显影响。王璐等［20］研究证实人工肝治疗对血小板计数的影响是暂时性的，基线血小板计数>80.5×109/L是降低人工肝治疗后出血风险的最佳界值。本研究根据血小板计数将其分为3组，据患者病情分别选择PP+PE、DPMAS+PE、PBA+PE不同模式人工肝，均使用Evacure-4A膜型选择性血浆分离器，结果显示，B、C组血小板计数治疗前后比较均有统计学差异（P值均<0.001）。3组患者治疗过程中均未发生出血，不良反应发生率无统计学差异（P>0.05）。说明Evacure-4A膜型选择性血浆分离器对血小板影响较小，对血小板明显低下ACLF患者行人工肝治疗是安全的。
多因素分析发现血小板是慢性肝病患者的独立预后因素之一［21］。肝病患者引起血小板减少的因素是多种多样的。有研究［22］表明，肝硬化和肝衰竭患者血小板减少的原因主要是肝脏凝血机制异常引起肝内弥散性血管内凝血形成，导致血小板的凝血消耗所致。许姗姗等［23］研究表明，ACLF患者基线血小板显著低于正常血小板的范围，血小板变化可能参与了ACLF的发生发展，其原因可能是参与肝脏微循环消耗所致。本研究中302例ACLF患者血小板计数呈不同程度的下降，其机制有待进一步探讨。人工肝治疗对肝衰竭患者的血细胞有一定影响，尤其是对PLT的破坏。选用对血小板影响较小的Evacure-4A膜型选择性血浆分离器，减少了人工肝治疗过程中对血小板的破坏，尤其对血小板计数在25×109/L～50×109/L分层组治疗前后无明显差异，亦未发生出血，在一定程度上拓宽了治疗的条件，对降低不良反应发生率及提高患者的抢救成功率有重要意义，值得临床进一步推广应用。
-
[1] LIN DN, CHEN H, XIONG J, et al. Mesenchymal stem cells exosomal let-7a-5p improve autophagic flux and alleviate liver injury in acute-on-chronic liver failure by promoting nuclear expression of TFEB[J]. Cell Death Dis, 2022, 13( 10): 865. DOI: 10.1038/s41419-022-05303-9. [2] Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure[J]. J Clin Hepatol, 2019, 35( 1): 38- 44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35( 1): 38- 44. DOI: 10.3969/j.issn.1001－5256.2019.01.007. [3] WLODZIMIROW KA, ESLAMI S, ABU-HANNA A, et al. Systematic review: Acute liver failure-one disease, more than 40 definitions[J]. Aliment Pharmacol Ther, 2012, 35( 11): 1245- 1256. DOI: 10.1111/j.1365-2036.2012.05097.x. [4] LI N, GU H, ZHU Y, et al. Recent progresses of the treatment of liver failure[J]. Med Philos B, 2018, 39( 8): 50- 54. DOI: 10.12014/j.issn.1002-0772.2018.08b.15.李娜, 顾欢, 朱英, 等. 肝衰竭治疗的最新进展[J]. 医学与哲学·B, 2018, 39( 8): 50- 54. DOI: 10.12014/j.issn.1002-0772.2018.08b.15. [5] MEZZANO G, JUANOLA A, CARDENAS A, et al. Global burden of disease: Acute-on-chronic liver failure, a systematic review and meta-analysis[J]. Gut, 2022, 71( 1): 148- 155. DOI: 10.1136/gutjnl-2020-322161. [6] YE YN, GAO ZL. Three attacks in the development of HBV-related liver failure[J]. Infect Dis Inf, 2009, 22( 5): 276- 279. DOI: 10.3969/j.issn.1007-8134.2009.05.006.叶一农, 高志良. 乙型肝炎肝衰竭发生机制中的三重打击[J]. 传染病信息, 2009, 22( 5): 276- 279. DOI: 10.3969/j.issn.1007-8134.2009.05.006. [7] AJOOLABADY A, KAPLOWITZ N, LEBEAUPIN C, et al. Endoplasmic reticulum stress in liver diseases[J]. Hepatology, 2023, 77( 2): 619- 639. DOI: 10.1002/hep.32562. [8] TORRES S, BAULIES A, INSAUSTI-URKIA N, et al. Endoplasmic reticulum stress-induced upregulation of STARD1 promotes acetaminophen-induced acute liver failure[J]. Gastroenterology, 2019, 157( 2): 552- 568. DOI: 10.1053/j.gastro.2019.04.023. [9] PRINZ E, AVIRAM S, ARONHEIM A. WDR62 mediates TNFα-dependent JNK activation via TRAF2-MLK3 axis[J]. Mol Biol Cell, 2018, 29( 20): 2470- 2480. DOI: 10.1091/mbc.E17-08-0504. [10] TABAS I, RON D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress[J]. Nat Cell Biol, 2011, 13( 3): 184- 190. DOI: 10.1038/ncb0311-184. [11] PLÜMPE J, MALEK NP, BOCK CT, et al. NF-kappaB determines between apoptosis and proliferation in hepatocytes during liver regeneration[J]. Am J Physiol Gastrointest Liver Physiol, 2000, 278( 1): G173- G183. DOI: 10.1152/ajpgi.2000.278.1.G173. [12] CZAJA MJ. The future of GI and liver research: Editorial perspectives. III. JNK/AP-1 regulation of hepatocyte death[J]. Am J Physiol Gastrointest Liver Physiol, 2003, 284( 6): G875- G879. DOI: 10.1152/ajpgi.00549.2002. [13] LIU W, JING ZT, WU SX, et al. PI3K/AKT inhibitors promote death receptor-mediated hepatocyte apoptosis and liver injury[C]// The Chinese Society of Biochemistry and Molecular Biology. Abstract Collection of the12th National Congress of theChinese Society of Biochemistry and Molecular Biology and the 2018 National Academic Conference. Chongqing, 2018: 113- 114.刘伟, 荆振唐, 吴淑香, 等. PI3K/akt抑制剂促进死亡受体介导的肝细胞凋亡及肝损伤[C]// 中国生物化学与分子生物学会第十二届全国会员代表大会暨2018年全国学术会议摘要集. 重庆, 2018: 113- 114. [14] HEINRICHSDORFF J, LUEDDE T, PERDIGUERO E, et al. p38 alpha MAPK inhibits JNK activation and collaborates with IkappaB kinase 2 to prevent endotoxin-induced liver failure[J]. EMBO Rep, 2008, 9( 10): 1048- 1054. DOI: 10.1038/embor.2008.149. [15] WANG KY, WEI DH, ZOU ZL, et al. Changes of MPO and Nrf2/HO-1 signaling pathway in D-GalN/LPS-induced acute liver failure in rats[J]. Chin J Crit Care Med, 2022, 42( 8): 717- 722. DOI: 10.3969/j.issn.1002-1949.2022.08.012.王柯尹, 魏大海, 邹卓林, 等. D-GalN/LPS诱导大鼠ALF中髓过氧化物酶和Nrf2/HO-1信号通路的变化[J]. 中国急救医学, 2022, 42( 8): 717- 722. DOI: 10.3969/j.issn.1002-1949.2022.08.012. [16] XU CY, BAILLY-MAITRE B, REED JC. Endoplasmic reticulum stress: Cell life and death decisions[J]. J Clin Invest, 2005, 115( 10): 2656- 2664. DOI: 10.1172/JCI26373. [17] LISBONA F, ROJAS-RIVERA D, THIELEN P, et al. BAX inhibitor-1 is a negative regulator of the ER stress sensor IRE1alpha[J]. Mol Cell, 2009, 33( 6): 679- 691. DOI: 10.1016/j.molcel.2009.02.017. [18] URANO F, WANG X, BERTOLOTTI A, et al. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1[J]. Science, 2000, 287( 5453): 664- 666. DOI: 10.1126/science.287.5453.664. [19] XIE YC, RAMACHANDRAN A, BRECKENRIDGE DG, et al. Inhibitor of apoptosis signal-regulating kinase 1 protects against acetaminophen-induced liver injury[J]. Toxicol Appl Pharmacol, 2015, 286( 1): 1- 9. DOI: 10.1016/j.taap.2015.03.019. [20] WANG CF, CHEN K, XIA YJ, et al. N-acetylcysteine attenuates ischemia-reperfusion-induced apoptosis and autophagy in mouse liver via regulation of the ROS/JNK/Bcl-2 pathway[J]. PLoS One, 2014, 9( 9): e108855. DOI: 10.1371/journal.pone.0108855. [21] BRENNER C, GALLUZZI L, KEPP O, et al. Decoding cell death signals in liver inflammation[J]. J Hepatol, 2013, 59( 3): 583- 594. DOI: 10.1016/j.jhep.2013.03.033. [22] ROTHE M, SARMA V, DIXIT VM, et al. TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40[J]. Science, 1995, 269( 5229): 1424- 1427. DOI: 10.1126/science.7544915. [23] SEKI E, BRENNER DA, KARIN M. A liver full of JNK: Signaling in regulation of cell function and disease pathogenesis, and clinical approaches[J]. Gastroenterology, 2012, 143( 2): 307- 320. DOI: 10.1053/j.gastro.2012.06.004. [24] HANAWA N, SHINOHARA M, SABERI B, et al. Role of JNK translocation to mitochondria leading to inhibition of mitochondria bioenergetics in acetaminophen-induced liver injury[J]. J Biol Chem, 2008, 283( 20): 13565- 13577. DOI: 10.1074/jbc.M708916200. [25] REN F, YANG BZ, ZHANG XY, et al. Role of endoplasmic reticulum stress in D-GalN/LPS-induced acute liver failure[J]. Chin J Hepatol, 2014, 22( 5): 364- 368. DOI: 10.3760/cma.j.issn.1007-3418.2014.05.009.任锋, 杨丙章, 张向颖, 等. 内质网应激在D-氨基半乳糖/脂多糖诱导小鼠急性肝衰竭中的作用[J]. 中华肝脏病杂志, 2014, 22( 5): 364- 368. DOI: 10.3760/cma.j.issn.1007-3418.2014.05.009. [26] RIAZ TA, JUNJAPPA RP, HANDIGUND M, et al. Role of endoplasmic reticulum stress sensor IRE1α in cellular physiology, calcium, ROS signaling, and metaflammation[J]. Cells, 2020, 9( 5): 1160. DOI: 10.3390/cells9051160. [27] KARAGÖZ GE, ACOSTA-ALVEAR D, NGUYEN HT, et al. An unfolded protein-induced conformational switch activates mammalian IRE1[J]. eLife, 2017, 6: e30700. DOI: 10.7554/eLife.30700. [28] LEE KP, DEY M, NECULAI D, et al. Structure of the dual enzyme Ire1 reveals the basis for catalysis and regulation in nonconventional RNA splicing[J]. Cell, 2008, 132( 1): 89- 100. DOI: 10.1016/j.cell.2007.10.057. [29] MA K, VATTEM KM, WEK RC. Dimerization and release of molecular chaperone inhibition facilitate activation of eukaryotic initiation factor-2 kinase in response to endoplasmic reticulum stress[J]. J Biol Chem, 2002, 277( 21): 18728- 18735. DOI: 10.1074/jbc.M200903200. [30] YE RS, JUNG DY, JUN JY, et al. Grp78 heterozygosity promotes adaptive unfolded protein response and attenuates diet-induced obesity and insulin resistance[J]. Diabetes, 2010, 59( 1): 6- 16. DOI: 10.2337/db09-0755. [31] INABA Y, FURUTANI T, KIMURA K, et al. Growth arrest and DNA damage-inducible 34 regulates liver regeneration in hepatic steatosis in mice[J]. Hepatology, 2015, 61( 4): 1343- 1356. DOI: 10.1002/hep.27619. [32] WU J, HE GT, ZHANG WJ, et al. IRE1α signaling pathways involved in mammalian cell fate determination[J]. Cell Physiol Biochem, 2016, 38( 3): 847- 858. DOI: 10.1159/000443039. [33] HUR KY, SO JS, RUDA V, et al. IRE1α activation protects mice against acetaminophen-induced hepatotoxicity[J]. J Exp Med, 2012, 209( 2): 307- 318. DOI: 10.1084/jem.20111298. [34] HAN D, LERNER AG, VANDE WALLE L, et al. IRE1alpha kinase activation modes control alternate endoribonuclease outputs to determine divergent cell fates[J]. Cell, 2009, 138( 3): 562- 575. DOI: 10.1016/j.cell.2009.07.017. [35] AHYI AN, QUINTON LJ, JONES MR, et al. Roles of STAT3 in protein secretion pathways during the acute-phase response[J]. Infect Immun, 2013, 81( 5): 1644- 1653. DOI: 10.1128/IAI.01332-12. [36] DUVIGNEAU JC, LUÍS A, GORMAN AM, et al. Crosstalk between inflammatory mediators and endoplasmic reticulum stress in liver diseases[J]. Cytokine, 2019, 124: 154577. DOI: 10.1016/j.cyto.2018.10.018. [37] LI YK, SCHWABE RF, DEVRIES-SEIMON T, et al. Free cholesterol-loaded macrophages are an abundant source of tumor necrosis factor-alpha and interleukin-6: Model of NF-kappaB-and map kinase-dependent inflammation in advanced atherosclerosis[J]. J Biol Chem, 2005, 280( 23): 21763- 21772. DOI: 10.1074/jbc.M501759200. [38] RASHID HO, KIM HK, JUNJAPPA R, et al. Endoplasmic reticulum stress in the regulation of liver diseases: Involvement of Regulated IRE1α and β-dependent decay and miRNA[J]. J Gastroenterol Hepatol, 2017, 32( 5): 981- 991. DOI: 10.1111/jgh.13619. [39] QI ZH, CHEN LX. Endoplasmic reticulum stress and autophagy[J]. Adv Exp Med Biol, 2019, 1206: 167- 177. DOI: 10.1007/978-981-15-0602-4_8. [40] LERNER AG, UPTON JP, PRAVEEN PVK, et al. IRE1α induces thioredoxin-interacting protein to activate the NLRP3 inflammasome and promote programmed cell death under irremediable ER stress[J]. Cell Metab, 2012, 16( 2): 250- 264. DOI: 10.1016/j.cmet.2012.07.007. [41] ZINDEL J, KUBES P. DAMPs, PAMPs, and LAMPs in immunity and sterile inflammation[J]. Annu Rev Pathol, 2020, 15: 493- 518. DOI: 10.1146/annurev-pathmechdis-012419-032847. [42] TANG Y, ZHOU XP, CAO T, et al. Endoplasmic reticulum stress and oxidative stress in inflammatory diseases[J]. DNA Cell Biol, 2022, 41( 11): 924- 934. DOI: 10.1089/dna.2022.0353. [43] XU HX, TIAN Y, TANG DM, et al. An endoplasmic reticulum stress-MicroRNA-26a feedback circuit in NAFLD[J]. Hepatology, 2021, 73( 4): 1327- 1345. DOI: 10.1002/hep.31428. [44] NÜRNBERGER S, MILLER I, DUVIGNEAU JC, et al. Impairment of endoplasmic reticulum in liver as an early consequence of the systemic inflammatory response in rats[J]. Am J Physiol Gastrointest Liver Physiol, 2012, 303( 12): G1373- G1383. DOI: 10.1152/ajpgi.00056.2012. [45] HIRAMATSU N, KASAI A, HAYAKAWA K, et al. Real-time detection and continuous monitoring of ER stress in vitro and in vivo by ES-TRAP: Evidence for systemic, transient ER stress during endotoxemia[J]. Nucleic Acids Res, 2006, 34( 13): e93. DOI: 10.1093/nar/gkl515. [46] TAM AB, KOONG AC, NIWA M. Ire1 has distinct catalytic mechanisms for XBP1/HAC1 splicing and RIDD[J]. Cell Rep, 2014, 9( 3): 850- 858. DOI: 10.1016/j.celrep.2014.09.016. [47] ZHANG KZ, SHEN XH, WU J, et al. Endoplasmic reticulum stress activates cleavage of CREBH to induce a systemic inflammatory response[J]. Cell, 2006, 124( 3): 587- 599. DOI: 10.1016/j.cell.2005.11.040. [48] MAUREL M, SAMALI A, CHEVET E. Endoplasmic reticulum stress: At the crossroads of inflammation and metabolism in hepatocellular carcinoma development[J]. Cancer Cell, 2014, 26( 3): 301- 303. DOI: 10.1016/j.ccr.2014.08.007. [49] BROZZI F, NARDELLI TR, LOPES M, et al. Cytokines induce endoplasmic reticulum stress in human, rat and mouse beta cells via different mechanisms[J]. Diabetologia, 2015, 58( 10): 2307- 2316. DOI: 10.1007/s00125-015-3669-6. [50] ZHAN F, ZHAO GP, LI X, et al. Inositol-requiring enzyme 1 alpha endoribonuclease specific inhibitor STF-083010 protects the liver from thioacetamide-induced oxidative stress, inflammation and injury by triggering hepatocyte autophagy[J]. Int Immunopharmacol, 2019, 73: 261- 269. DOI: 10.1016/j.intimp.2019.04.051. [51] LEI Y, WANG SL, REN BS, et al. CHOP favors endoplasmic reticulum stress-induced apoptosis in hepatocellular carcinoma cells via inhibition of autophagy[J]. PLoS One, 2017, 12( 8): e0183680. DOI: 10.1371/journal.pone.0183680. [52] TIAN RD, CHEN YQ, HE YH, et al. Phosphorylation of eIF2α mitigates endoplasmic reticulum stress and hepatocyte necroptosis in acute liver injury[J]. Ann Hepatol, 2020, 19( 1): 79- 87. DOI: 10.1016/j.aohep.2019.05.008. [53] WANG S, LUAN JJ, LV XW. Inhibition of endoplasmic reticulum stress attenuated ethanol-induced exosomal miR-122 and acute liver injury in mice[J]. Alcohol Alcohol, 2019, 54( 5): 465- 471. DOI: 10.1093/alcalc/agz058. [54] WANG XF, ZHANG X, WANG F, et al. FGF1 protects against APAP-induced hepatotoxicity via suppression of oxidative and endoplasmic reticulum stress[J]. Clin Res Hepatol Gastroenterol, 2019, 43( 6): 707- 714. DOI: 10.1016/j.clinre.2019.03.006. [55] QI J, CHEN X, ZHANG C, et al. Effects of 4-phenylbutyric acid on carbon tetrachloride-induced acute liver injury in mice[J]. Chin J Hepatol, 2015, 23( 4): 286- 291. DOI: 10.3760/cma.j.issn.1007-3418.2015.04.011.齐军, 陈熙, 张程, 等. 4-苯基丁酸对四氯化碳诱导小鼠急性肝损伤的影响[J]. 中华肝脏病杂志, 2015, 23( 4): 286- 291. DOI: 10.3760/cma.j.issn.1007-3418.2015.04.011. [56] LI WY, YANG F, LI X, et al. Stress granules inhibit endoplasmic reticulum stress-mediated apoptosis during hypoxia-induced injury in acute liver failure[J]. World J Gastroenterol, 2023, 29( 8): 1315- 1329. DOI: 10.3748/wjg.v29.i8.1315. [57] ABO-ZAID OA, MOAWED FS, ISMAIL ES, et al. β-Sitosterol mitigates hepatocyte apoptosis by inhibiting endoplasmic reticulum stress in thioacetamide-induced hepatic injury in γ-irradiated rats[J]. Food Chem Toxicol, 2023, 172: 113602. DOI: 10.1016/j.fct.2023.113602. [58] DESHMUKH K, APTE U. The role of endoplasmic reticulum stress response in liver regeneration[J]. Semin Liver Dis, 2023, 43( 3): 279- 292. DOI: 10.1055/a-2129-8977. [59] ALHUTHALI HM, BRADSHAW TD, LIM KH, et al. The natural alkaloid Jerantinine B has activity in acute myeloid leukemia cells through a mechanism involving c-Jun[J]. BMC Cancer, 2020, 20( 1): 629. DOI: 10.1186/s12885-020-07119-2. [60] HUANG CC, WANG JM, KIKKAWA U, et al. Calcineurin-mediated dephosphorylation of c-Jun Ser-243 is required for c-Jun protein stability and cell transformation[J]. Oncogene, 2008, 27( 17): 2422- 2429. DOI: 10.1038/sj.onc.1210888. [61] CHEN XG, LV QX, MA J, et al. PLCγ2 promotes apoptosis while inhibits proliferation in rat hepatocytes through PKCD/JNK MAPK and PKCD/p38 MAPK signalling[J]. Cell Prolif, 2018, 51( 3): e12437. DOI: 10.1111/cpr.12437. [62] KHAMPHAYA T, CHUKIJRUNGROAT N, SAENGSIRISUWAN V, et al. Nonalcoholic fatty liver disease impairs expression of the type II inositol 1, 4, 5-trisphosphate receptor[J]. Hepatology, 2018, 67( 2): 560- 574. DOI: 10.1002/hep.29588. [63] XIONG YL, WANG YM, XIONG YL, et al. Salidroside alleviated hypoxia-induced liver injury by inhibiting endoplasmic reticulum stress-mediated apoptosis via IRE1α/JNK pathway[J]. Biochem Biophys Res Commun, 2020, 529( 2): 335- 340. DOI: 10.1016/j.bbrc.2020.06.036. [64] GAO JM, WANG TT, BIAO YN, et al. Broussonetiae fructus protects against APAP-induced liver injury in mice by inhibiting endoplasmic reticulum stress pathway[J]. Chin J Exp Tradit Med Formulae, 2022, 28( 16): 66- 73. DOI: 10.13422/j.cnki.syfjx.20221544.高晶淼, 王婷婷, 彪雅宁, 等. 楮实子通过抑制ERS途径保护APAP诱导的小鼠肝损伤[J]. 中国实验方剂学杂志, 2022, 28( 16): 66- 73. DOI: 10.13422/j.cnki.syfjx.20221544. [65] ZHANG JX, YIN J, QU XL, et al. Effects of compatibility of Schisandra chinensis on Psoralea corylifolia-induced oxidative damage and endoplasmic reticulum stress in hepatocytes[J]. China Pharm, 2022, 33( 9): 1088- 1093. DOI: 10.6039/j.issn.1001-0408.2022.09.11.张婧茜, 殷佳, 曲晓琳, 等. 五味子配伍对补骨脂致肝细胞氧化损伤和ERS的影响[J]. 中国药房, 2022, 33( 9): 1088- 1093. DOI: 10.6039/j.issn.1001-0408.2022.09.11. [66] WU YL, LIAN LH, WAN Y, et al. Baicalein inhibits nuclear factor-κB and apoptosis via c-FLIP and MAPK in D-GalN/LPS induced acute liver failure in murine models[J]. Chem Biol Interact, 2010, 188( 3): 526- 534. DOI: 10.1016/j.cbi.2010.09.008. [67] KIM SJ, KIM JK, LEE DU, et al. Genipin protects lipopolysaccharide-induced apoptotic liver damage in D-galactosamine-sensitized mice[J]. Eur J Pharmacol, 2010, 635( 1-3): 188- 193. DOI: 10.1016/j.ejphar.2010.03.007. [68] WANG HJ, CHEN LY, ZHANG XY, et al. Kaempferol protects mice from d-GalN/LPS-induced acute liver failure by regulating the ER stress-Grp78-CHOP signaling pathway[J]. Biomedecine Pharmacother, 2019, 111: 468- 475. DOI: 10.1016/j.biopha.2018.12.105. [69] WEN JJ, LIN HF, ZHAO MS, et al. Piceatannol attenuates D-GalN/LPS-induced hepatoxicity in mice: Involvement of ER stress, inflammation and oxidative stress[J]. Int Immunopharmacol, 2018, 64: 131- 139. DOI: 10.1016/j.intimp.2018.08.037. [70] LIU H, ZHANG W, DONG SC, et al. Protective effects of sea buckthorn polysaccharide extracts against LPS/d-GalN-induced acute liver failure in mice via suppressing TLR4-NF-κB signaling[J]. J Ethnopharmacol, 2015, 176: 69- 78. DOI: 10.1016/j.jep.2015.10.029. [71] TAI MH, ZHANG JY, SONG SD, et al. Protective effects of luteolin against acetaminophen-induced acute liver failure in mouse[J]. Int Immunopharmacol, 2015, 27( 1): 164- 170. DOI: 10.1016/j.intimp.2015.05.009. -
下载:
下载:
